CLSPN and prostate carcinoma: Claspin expression was found to be enhanced in docetaxel-resistant prostate cancer cells, and functional studies demonstrated that docetaxel sensitivity could be restored by silencing Claspin, which was associated with reduced activation of the Akt and Erk pathway, and a consequent decrease in survival signals [99].